Adam Maeder
Stock Analyst at Piper Sandler
(4.08)
# 455
Out of 4,784 analysts
95
Total ratings
55.38%
Success rate
11.17%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $11 → $8.5 | $6.17 | +37.76% | 7 | Mar 18, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $70 → $73 | $70.91 | +2.95% | 13 | Feb 12, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $260 → $233 | $157.24 | +48.18% | 14 | Feb 10, 2025 | |
| NVRO Nevro | Upgrades: Neutral | $6 → $5.85 | $5.84 | +0.17% | 16 | Feb 7, 2025 | |
| RMD ResMed | Maintains: Neutral | $252 → $260 | $219.94 | +18.21% | 2 | Jan 31, 2025 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $538 → $670 | $491.84 | +36.22% | 18 | Jan 24, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $131 → $133 | $130.82 | +1.67% | 2 | Oct 17, 2024 | |
| NSPR InspireMD | Reiterates: Overweight | $4.5 | $2.70 | +66.67% | 3 | Sep 17, 2024 | |
| M Macy's | Maintains: Hold | $20 → $21 | $12.81 | +63.93% | 2 | May 22, 2024 | |
| STIM Neuronetics | Reiterates: Overweight | $7 → $8 | $3.77 | +112.20% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $7.65 | +161.44% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $13.00 | +130.77% | 2 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.80 | +177.78% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $2.25 | +700.00% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $39.13 | +153.00% | 3 | May 5, 2022 |
Vicarious Surgical
Mar 18, 2025
Maintains: Neutral
Price Target: $11 → $8.5
Current: $6.17
Upside: +37.76%
Edwards Lifesciences
Feb 12, 2025
Maintains: Neutral
Price Target: $70 → $73
Current: $70.91
Upside: +2.95%
Inspire Medical Systems
Feb 10, 2025
Maintains: Overweight
Price Target: $260 → $233
Current: $157.24
Upside: +48.18%
Nevro
Feb 7, 2025
Upgrades: Neutral
Price Target: $6 → $5.85
Current: $5.84
Upside: +0.17%
ResMed
Jan 31, 2025
Maintains: Neutral
Price Target: $252 → $260
Current: $219.94
Upside: +18.21%
Intuitive Surgical
Jan 24, 2025
Reiterates: Overweight
Price Target: $538 → $670
Current: $491.84
Upside: +36.22%
Abbott Laboratories
Oct 17, 2024
Maintains: Overweight
Price Target: $131 → $133
Current: $130.82
Upside: +1.67%
InspireMD
Sep 17, 2024
Reiterates: Overweight
Price Target: $4.5
Current: $2.70
Upside: +66.67%
Macy's
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $12.81
Upside: +63.93%
Neuronetics
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $3.77
Upside: +112.20%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $7.65
Upside: +161.44%
May 9, 2023
Maintains: Overweight
Price Target: $25 → $30
Current: $13.00
Upside: +130.77%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $1.80
Upside: +177.78%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $2.25
Upside: +700.00%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $39.13
Upside: +153.00%